34737-89-8

Usage

Uses

1-Benzyl-3-methyl-4-piperidone is used as an intermediate in the pharmaceutical industry for the preparation of Fentanyl (F274990) analogs. These analogs exhibit potent analgesic activity, making them valuable in the development of pain-relieving medications.
Used in Pharmaceutical Industry:
1-Benzyl-3-methyl-4-piperidone is used as a key component in the synthesis of Fentanyl analogs for their analgesic properties. 1-Benzyl-3-methyl-4-piperidone contributes to the development of effective pain management solutions, particularly for severe and chronic pain conditions.

InChI:InChI=1/C5H4N2O/c8-4-5-3-6-1-2-7-5/h1-4H

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 74-88-4 methyl iodide 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 1589566-76-6 2-methyl-3-[(2-iodoethyl)(phenylmethyl)amino]-propanoic acid 
• 1285576-65-9 C₁₄H₂₁NO₃ 
• 127956-04-1 ethyl 1-benzyl-3-methyl-4-oxopiperidine-3-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 7006-50-0 1-benzyl-N-methylpiperidin-4-amine 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 103-80-0 phenylacetyl chloride 

Downstream Products

• 53757-54-3 (+/-)-cis-3-methyl-N-phenyl-4-piperidinamine 
• 53757-51-0 (3S,4R)-(-)-cis-3-methyl-N-phenyl-4-piperidinamine 
• 163181-24-6 (3R,4S)-cis-(+)-3-methyl-1-(2-oxo-2-phenylethyl)-N-phenyl-4-piperidinamine 
• 163181-28-0 (3S,4R)-cis-(-)-3-methyl-1-(2-oxo-2-phenylethyl)-N-phenyl-4-piperidinamine 
• 188868-66-8 (3RS,4SR)-1-benzyl-4-(4-fluoro-phenyl)-3-methyl-piperidine-4-ol 
• 181269-69-2 tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate 
• 173186-91-9 N-benzyl-3,3-dimethylpiperidine-4-one 
• 836-21-5 1-Benzyl-3,5-dimethyl-piperidin-4-one 
• 42045-85-2 N-((3S,4R)-1-Benzyl-3-methyl-piperidin-4-yl)-N-phenyl-propionamide; hydrochloride 
• 42045-85-2 N-((3R,4R)-1-Benzyl-3-methyl-piperidin-4-yl)-N-phenyl-propionamide; hydrochloride 
• 97220-08-1 cis-N-(3-methyl-1-<2-(1,2,3,4-tetrahydro)naphthyl>-4-piperidinyl)-N-phenylpropanamide 
• 97220-08-1 trans-N-(3-methyl-1-<2-(1,2,3,4-tetrahydro)naphthyl>-4-piperidinyl)-N-phenylpropanamide 
• 42045-84-1 cis-N-<3-methyl-1-(phenylmethyl)-4-piperidinyl>-N-phenylpropanamide 
• 42045-84-1 trans-N-<3-methyl-1-(phenylmethyl)-4-piperidinyl>-N-phenylpropanamide 

Relevant academic research and scientific papers

INTERMEDIATES FOR OPTICALLY ACTIVE PIPERIDINE DERIVATIVES AND PREPARATION METHODS THEREOF

A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.

NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.

5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them

The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) in which the variables are as described herein.

A novel and concise synthetic access to chiral 2-substituted-4-piperidone

A novel and concise synthetic access to enantiopure chiral 2-aryl/alkyl substituted 4-piperidone has been demonstrated. This new route features two key steps: the highly diastereoselective conjugate addition of homochiral lithium amides to trans-β-substituted-α,β-unsaturated methyl esters guaranteed the enantiopurity at 2 position (de >19:1) and the intramolecular attacking of carbanions to methyl esters led to the formation of the piperidone ring. A wide range of substrates, including chiral 2-aryl and 2-alkyl-4-piperidones, were successfully synthesized with modest to high yield. Moreover, some non-chiral 3-substituted-4-piperidones were also synthesized with enhanced ring-formation yield, implicating the versatility of this method in construction of various piperidine rings.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments

This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I, II, III, IV, V, and VI) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compounds of formula (I) as disclosed herein can be used in a variety of applications including use as antibacterial agents.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.

Tetrahydroisoquinoline derivative and medical preparation containing the same

The present invention relates to a tetrahydroisoquinoline derivative represented by the following formula 1 exhibiting an inhibitory action for agglutination caused by fibrinogen, which may be effectively used as an antithrombotic agent or a platelet agglutination-inhibiting agent. The present invention also relates to a medical preparation containing such compound. STR1 In formula 1, B and G are an alkylene optionally substituted with an alkyl or the like; D is H, an alkyl, or the like; E is 1,2,3,4-tetrahydroisoquinoline optionally substituted with R1 to R4 which binds to G at position 2; R1 to R4 are an alkyl or the like; L is hydroxy or the like; and A is a substituent represented by formula (2), and C is carbon. STR2 In formula 2, M and R5 to R8 are H, an alkyl or the like.